On September 8, 2022 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), reported that the Company will hold a conference call on Thursday, September 15, 2022, to give an update on business progress during the first half of 2022 (Press release, Innate Pharma, SEP 8, 2022, View Source [SID1234619277]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Speakers during the call will be:

Mondher Mahjoubi, Chief Executive Officer
Joyson Karakunnel, Executive Vice President, Chief Medical Officer
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Yannis Morel, Executive Vice President, Product Portfolio Strategy & Business Development
Details for the Virtual Event

Participants may also join via telephone to ask questions by registering in advance of the event at: View Source Upon registration, participants will be provided with dial-in numbers, a direct event passcode and a unique registrant ID that they may use 10 minutes prior to the event start to access the call. Call reminders will also be sent to registered participants via e-mail the day prior to the event.

This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event.